situation going on today at ARIA. Yesterday after hours the ODAC commitee rejected their drug ridoforamlinus 13-1, and all the shorts bombarded the board with gloom and doom. Today the stock up 4% last I checked. The ignorant shorts haven't done their homework on ARIA and noticed their pipeline drug Ponatinib is the potential blockbuster that has been moving this company higher. Everyone knew Rido would be a close call with the FDA, but Pon is the real deal. Much like SGN 35 before approval although with a potentially much larger target patient population.